Mark Schoenberg - Oct 31, 2021 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Medical Officer
Signature
/s/ Jason Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Oct 31, 2021
Transactions value $
-$4,427
Form type
4
Date filed
11/2/2021, 03:45 PM
Previous filing
Oct 28, 2021
Next filing
Nov 19, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +500 +2.32% 22.1K Oct 31, 2021 Direct F1
transaction URGN Ordinary Shares Sale -$4.43K -258 -1.17% $17.16 21.8K Nov 1, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -500 -16.67% $0.00 2.5K Oct 31, 2021 Ordinary Shares 500 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units
F3 The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.